SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval Eligibility for Accelerated Read More

PALO ALTO, CA. August 17, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement Read More

30 million lives now covered by one of the largest national PBMs  Continue to work with this PBM to access an additional 20 million lives  The team continues to work with the national PBM’s and health plans to improve access further during 2022 with a goal to reach 250 million to 260 million lives Read More

Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-operative periods associated with general and Read More

PALO ALTO, CA. July 5, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for Read More

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States 1 . As gout cases increase every year, treatment requirements increase. Read More

PALO ALTO and SAN DIEGO, CA. June 3, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid Read More

Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered by managed health care plans representing approximately 190 million of the over 300 million covered Read More

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower back pain.  The trial will enroll 80 patients with acute lower back pain. Read More

PALO ALTO, CA. and NEW YORK, NY. May 16, 2022 /Newswire/ – – Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nasdaq: VCKA “Vickers”) today announced the Read More